174 related articles for article (PubMed ID: 33757557)
21. Anti-hepatitis B virus activity of lithospermic acid, a polyphenol from Salvia miltiorrhiza, in vitro and in vivo by autophagy regulation.
Zhu S; Wen H; Wang W; Chen Y; Han F; Cai W
J Ethnopharmacol; 2023 Feb; 302(Pt A):115896. PubMed ID: 36334815
[TBL] [Abstract][Full Text] [Related]
22. Treatment with a New Barbituric Acid Derivative Exerts Antiproliferative and Antimigratory Effects against Sorafenib Resistance in Hepatocellular Carcinoma.
Liao YJ; Hsu SM; Chien CY; Wang YH; Hsu MH; Suk FM
Molecules; 2020 Jun; 25(12):. PubMed ID: 32575795
[TBL] [Abstract][Full Text] [Related]
23. Hepatitis B virus suppresses the secretion of insulin-like growth factor binding protein 1 to facilitate anti-apoptotic IGF-1 effects in HepG2 cells.
Nielsen KO; Mirza AH; Kaur S; Jacobsen KS; Winther TN; Glebe D; Pociot F; Hogh B; Størling J
Exp Cell Res; 2018 Sep; 370(2):399-408. PubMed ID: 29981339
[TBL] [Abstract][Full Text] [Related]
24. Oxymatrine inhibits hepatitis B infection with an advantage of overcoming drug-resistance.
Wang YP; Zhao W; Xue R; Zhou ZX; Liu F; Han YX; Ren G; Peng ZG; Cen S; Chen HS; Li YH; Jiang JD
Antiviral Res; 2011 Mar; 89(3):227-31. PubMed ID: 21277330
[TBL] [Abstract][Full Text] [Related]
25. MiR-3677-3p promotes development and sorafenib resistance of hepatitis B-related hepatocellular carcinoma by inhibiting FOXM1 ubiquitination.
He H; Zhou J; Cheng F; Li H; Quan Y
Hum Cell; 2023 Sep; 36(5):1773-1789. PubMed ID: 37402927
[TBL] [Abstract][Full Text] [Related]
26. Valproic acid reverses sorafenib resistance through inhibiting activated Notch/Akt signaling pathway in hepatocellular carcinoma.
Yang X; Liu J; Liang Q; Sun G
Fundam Clin Pharmacol; 2021 Aug; 35(4):690-699. PubMed ID: 33015852
[TBL] [Abstract][Full Text] [Related]
27. miR-23b-3p Modulating Cytoprotective Autophagy and Glutamine Addiction in Sorafenib Resistant HepG2, a Hepatocellular Carcinoma Cell Line.
Kaur R; Kanthaje S; Taneja S; Dhiman RK; Chakraborti A
Genes (Basel); 2022 Aug; 13(8):. PubMed ID: 36011286
[TBL] [Abstract][Full Text] [Related]
28. High mobility group box 1 promotes sorafenib resistance in HepG2 cells and in vivo.
Xiao Y; Sun L; Fu Y; Huang Y; Zhou R; Hu X; Zhou P; Quan J; Li N; Fan XG
BMC Cancer; 2017 Dec; 17(1):857. PubMed ID: 29246127
[TBL] [Abstract][Full Text] [Related]
29. Long noncoding RNA SNHG16 induces sorafenib resistance in hepatocellular carcinoma cells through sponging miR-140-5p.
Ye J; Zhang R; Du X; Chai W; Zhou Q
Onco Targets Ther; 2019; 12():415-422. PubMed ID: 30655679
[TBL] [Abstract][Full Text] [Related]
30. Brassicasterol inhibits hepatitis B virus-associated hepatocellular carcinoma development via suppression of AKT signaling pathway.
Zeng J; Wu J; Pang S; Wang F; Yu X; Zhang S; Zeng J; Yan J; Lian J
Infect Agent Cancer; 2023 Apr; 18(1):22. PubMed ID: 37081537
[TBL] [Abstract][Full Text] [Related]
31. Mitomycin, 5-fluorouracil, leflunomide, and mycophenolic acid directly promote hepatitis B virus replication and expression in vitro.
Ruan J; Sun S; Cheng X; Han P; Zhang Y; Sun D
Virol J; 2020 Jul; 17(1):89. PubMed ID: 32611423
[TBL] [Abstract][Full Text] [Related]
32. [Y-box-binding protein 1 mediates sorafenib resistance via the extracellular signal regulated-protein kinase pathway in hepatoma cells].
Liu T; Xie XL; Chen SX; Wang YJ; Jiang HQ
Zhonghua Gan Zang Bing Za Zhi; 2023 Apr; 31(4):401-407. PubMed ID: 37248979
[No Abstract] [Full Text] [Related]
33. Discovery of novel quinazolinone derivatives as potential anti-HBV and anti-HCC agents.
Qiu J; Zhou Q; Zhang Y; Guan M; Li X; Zou Y; Huang X; Zhao Y; Chen W; Gu X
Eur J Med Chem; 2020 Nov; 205():112581. PubMed ID: 32791397
[TBL] [Abstract][Full Text] [Related]
34. Vimentin as a potential therapeutic target in sorafenib resistant HepG2, a HCC model cell line.
Makol A; Kaur H; Sharma S; Kanthaje S; Kaur R; Chakraborti A
Clin Mol Hepatol; 2020 Jan; 26(1):45-53. PubMed ID: 31564085
[TBL] [Abstract][Full Text] [Related]
35. Effect of interferon-γ and tumor necrosis factor-α on hepatitis B virus following lamivudine treatment.
Shi H; Lu L; Zhang NP; Zhang SC; Shen XZ
World J Gastroenterol; 2012 Jul; 18(27):3617-22. PubMed ID: 22826629
[TBL] [Abstract][Full Text] [Related]
36. Validation of VX2 as a Hepatocellular Carcinoma Model: Comparison of the Molecular Reaction of VX2 and HepG2 Tumor Cells to Sorafenib In Vitro.
Nass N; Streit S; Wybranski C; Jürgens J; Brauner J; Schulz N; Powerski M; Ricke J; Kalinski T; Dudeck O; Seidensticker M
Anticancer Res; 2017 Jan; 37(1):87-93. PubMed ID: 28011478
[TBL] [Abstract][Full Text] [Related]
37. The lncRNA lnc-TSI antagonizes sorafenib resistance in hepatocellular carcinoma via downregulating miR-4726-5p expression and upregulating KCNMA1 expression.
Chen F; Jiang J; Liu D; Li H; Dong L; Song Y; Zhang Y; Wang J; Qin Y; Zhao G
J Mol Histol; 2024 Feb; 55(1):83-96. PubMed ID: 38165571
[TBL] [Abstract][Full Text] [Related]
38. Combination of small interfering RNA and lamivudine on inhibition of human B virus replication in HepG2.2.15 cells.
Li GQ; Xu WZ; Wang JX; Deng WW; Li D; Gu HX
World J Gastroenterol; 2007 Apr; 13(16):2324-7. PubMed ID: 17511031
[TBL] [Abstract][Full Text] [Related]
39. Inhibitory effects of crude extracts from some edible Thai plants against replication of hepatitis B virus and human liver cancer cells.
Waiyaput W; Payungporn S; Issara-Amphorn J; Panjaworayan NT
BMC Complement Altern Med; 2012 Dec; 12():246. PubMed ID: 23216691
[TBL] [Abstract][Full Text] [Related]
40. Glucose-regulated protein 78 demonstrates antiviral effects but is more suitable for hepatocellular carcinoma prevention in hepatitis B.
Zheng NQ; Zheng ZH; Xu HX; Huang MX; Peng XM
Virol J; 2017 Apr; 14(1):77. PubMed ID: 28407787
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
